{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:11:05Z","timestamp":1778217065145,"version":"3.51.4"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Shenzhen Medical Research Fund","award":["D2404003"],"award-info":[{"award-number":["D2404003"]}]},{"DOI":"10.13039\/501100012151","name":"Sanming Project of Medicine in Shenzhen","doi-asserted-by":"publisher","award":["SZSM202103014"],"award-info":[{"award-number":["SZSM202103014"]}],"id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Primary cutaneous amyloidosis (PCA) is a chronic, severely pruritic dermatosis characterized by amyloid deposition in the dermis. There is currently no standardized treatment for PCA, and its clinical management remains challenging. Ivarmacitinib, a novel, highly selective oral Janus kinase 1 (JAK1) inhibitor, has demonstrated significant efficacy in modulating inflammatory and pruritic pathways in atopic dermatitis (AD), suggesting its potential utility in related conditions. We report a compelling case of a 65-year-old male with a 15-year history of severe, refractory PCA who had failed multiple conventional treatments, including topical corticosteroids, systemic retinoids, and immunomodulators, owing to either poor tolerability or insufficient efficacy. Thus, ivarmacitinib was initiated as a targeted therapeutic intervention, and it resulted in rapid improvement: pruritus subsided within 24\u202fh and resolved completely within one week, followed by significant flattening and fading of hyperpigmented papules over the ensuing weeks, with no adverse events observed during follow-up. This case suggests that ivarmacitinib may be a promising, effective, and well-tolerated therapeutic option for refractory PCA, likely through targeting the JAK\/STAT pathway central to disease pathogenesis.<\/jats:p>","DOI":"10.3389\/fmed.2026.1803727","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T04:45:23Z","timestamp":1778215523000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Ivarmacitinib in the treatment of refractory primary cutaneous amyloidosis"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiaofan","family":"Liao","sequence":"first","affiliation":[{"name":"Department of Dermatology, Affiliated Nanshan Hospital of Shenzhen University","place":["Shenzhen, China"]},{"name":"Medical School, Shenzhen University","place":["Shenzhen, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xian","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Affiliated Nanshan Hospital of Shenzhen University","place":["Shenzhen, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Chinese University of Hong Kong, Shenzhen Medical Centre","place":["Shenzhen, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Affiliated Nanshan Hospital of Shenzhen University","place":["Shenzhen, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qifeng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pathology, Affiliated Nanshan Hospital of Shenzhen University","place":["Shenzhen, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Affiliated Nanshan Hospital of Shenzhen University","place":["Shenzhen, China"]},{"name":"Medical School, Shenzhen University","place":["Shenzhen, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"ref1","first-page":"282","article-title":"Primary amyloidosis of the breast presenting as a solitary nodule: case report and review of the literature","volume":"14","author":"Huerter","year":"2014","journal-title":"Ochsner J"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1111\/bjd.13078","article-title":"Primary nodular amyloidosis of the glans penis","volume":"171","author":"Di Meo","year":"2014","journal-title":"Br J Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e12743","DOI":"10.1111\/dth.12743","article-title":"Biphasic amyloidosis involved in the face: effective treatment with 30% salicylic acid","volume":"32","author":"Wang","year":"2019","journal-title":"Dermatol Ther"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s40257-017-0278-9","article-title":"Primary localized cutaneous amyloidosis: a systematic treatment review","volume":"18","author":"Weidner","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1093\/ced\/llaf081","article-title":"A systematic review and meta-analysis of treatments and outcomes of primary localized cutaneous amyloidosis","volume":"50","author":"Wang","year":"2025","journal-title":"Clin Exp Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"306","DOI":"10.23736\/S2784-8671.22.07265-6","article-title":"The emerging role of the neuroimmune cytokine interleukin-31 in chronic inflammatory skin diseases","volume":"157","author":"Girolomoni","year":"2022","journal-title":"Ital J Dermatol Venerol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"634","DOI":"10.3390\/biom13040634","article-title":"Dupilumab in inflammatory skin diseases: a systematic review","volume":"13","author":"Olbrich","year":"2023","journal-title":"Biomolecules"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s40257-021-00620-9","article-title":"Primary localized cutaneous amyloidosis of keratinocyte origin: an update with emphasis on atypical clinical variants","volume":"22","author":"Hamie","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ajhg.2007.09.002","article-title":"Oncostatin M receptor-beta mutations underlie familial primary localized cutaneous amyloidosis","volume":"82","author":"Arita","year":"2008","journal-title":"Am J Hum Genet"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/bjd.14207","article-title":"The first trial of CIM331, a humanized antihuman interleukin-31 receptor a antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study","volume":"174","author":"Nemoto","year":"2016","journal-title":"Br J Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","article-title":"JAK inhibitors in dermatology: the promise of a new drug class","volume":"76","author":"Damsky","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1007\/s40265-025-02202-z","article-title":"Ivarmacitinib sulfate: first approval","volume":"85","author":"Keam","year":"2025","journal-title":"Drugs"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1001\/jamadermatol.2025.0982","article-title":"Ivarmacitinib for moderate to severe atopic dermatitis in adults and adolescents: a phase 3 randomized clinical trial","volume":"161","author":"Zhao","year":"2025","journal-title":"JAMA Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e15724","DOI":"10.1111\/dth.15724","article-title":"Refractory cutaneous lichen amyloidosis coexisting with atopic dermatitis responds to the Janus kinase inhibitor baricitinib","volume":"35","author":"Xia","year":"2022","journal-title":"Dermatol Ther"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e480","DOI":"10.1111\/ijd.16698","article-title":"Treatment of primary cutaneous lichenoid amyloidosis with abrocitinib: a pilot study in two cases","volume":"62","author":"Bai","year":"2023","journal-title":"Int J Dermatol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1803727\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T04:45:46Z","timestamp":1778215546000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1803727\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":15,"alternative-id":["10.3389\/fmed.2026.1803727"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1803727","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"article-number":"1803727"}}